AU2020357866A1 - Targeted pulmonary delivery compositions and methods using same - Google Patents

Targeted pulmonary delivery compositions and methods using same Download PDF

Info

Publication number
AU2020357866A1
AU2020357866A1 AU2020357866A AU2020357866A AU2020357866A1 AU 2020357866 A1 AU2020357866 A1 AU 2020357866A1 AU 2020357866 A AU2020357866 A AU 2020357866A AU 2020357866 A AU2020357866 A AU 2020357866A AU 2020357866 A1 AU2020357866 A1 AU 2020357866A1
Authority
AU
Australia
Prior art keywords
solid particle
phage
subject
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020357866A
Other languages
English (en)
Inventor
Wadih Arap
Renata Pasqualini
Daniela STAQUICINI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers State University of New Jersey
Original Assignee
Rutgers State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers State University of New Jersey filed Critical Rutgers State University of New Jersey
Publication of AU2020357866A1 publication Critical patent/AU2020357866A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020357866A 2019-10-04 2020-10-01 Targeted pulmonary delivery compositions and methods using same Pending AU2020357866A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962910998P 2019-10-04 2019-10-04
US62/910,998 2019-10-04
PCT/US2020/053758 WO2021067571A1 (en) 2019-10-04 2020-10-01 Targeted pulmonary delivery compositions and methods using same

Publications (1)

Publication Number Publication Date
AU2020357866A1 true AU2020357866A1 (en) 2022-04-21

Family

ID=75337530

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020357866A Pending AU2020357866A1 (en) 2019-10-04 2020-10-01 Targeted pulmonary delivery compositions and methods using same

Country Status (6)

Country Link
US (1) US20220332759A1 (https=)
EP (1) EP4041276A4 (https=)
JP (1) JP7692218B2 (https=)
AU (1) AU2020357866A1 (https=)
CA (1) CA3153476A1 (https=)
WO (1) WO2021067571A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230241203A1 (en) * 2020-07-06 2023-08-03 Rutgers, The State University Of New Jersey Enhancing immune responses through targeted antigen expression

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041814B1 (en) * 1998-02-18 2006-05-09 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Enterobacter cloacae for diagnostics and therapeutics
US20050036951A1 (en) * 2003-01-09 2005-02-17 Arizeke Pharmaceuticals, Inc. Methods of treating lung diseases
US7659252B2 (en) * 2005-09-15 2010-02-09 Novomed Technologies, Inc. (Shanghai) Transdermal delivery peptides and method of use thereof

Also Published As

Publication number Publication date
JP2022550452A (ja) 2022-12-01
EP4041276A4 (en) 2024-02-07
WO2021067571A1 (en) 2021-04-08
JP7692218B2 (ja) 2025-06-13
CA3153476A1 (en) 2021-04-08
US20220332759A1 (en) 2022-10-20
EP4041276A1 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
CN105452270B (zh) 流行性感冒病毒疫苗及其用途
WO2022262142A1 (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
KR20220142472A (ko) 감염을 치료하거나 또는 감염의 진행을 제한하기 위한 폴리펩타이드, 조성물 및 그 용도
KR20190056382A (ko) 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
CN101022827A (zh) 用于治疗冠状病毒感染的疫苗组合物
JP2005532276A (ja) 免疫化組成物およびアミロイド前駆体タンパク質のβ−セクレターゼ開裂部位に対する免疫応答を誘発する方法
US20240294580A1 (en) Compositions and methods of ribonucleic acid respiratory syncytial virus (rsv) vaccines
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
CN118119930A (zh) 抗新型冠状病毒感染的mRNA疫苗的组合物和方法
US20230241203A1 (en) Enhancing immune responses through targeted antigen expression
US8722055B2 (en) Synthetic Streptococcus pneumoniae vaccine
WO2022162012A2 (en) Antibodies broadly targeting coronaviruses and uses thereof
JP7692218B2 (ja) ターゲティングされた肺送達組成物およびそれを使用する方法
US12144866B2 (en) Transferrin binding antibodies and use thereof
US20240226279A1 (en) Human anti-coronavirus peptide vaccines and methods of their use
WO2023069971A2 (en) Cd24-loaded vesicles for treatment of cytokine storm and other conditions
US20260083836A1 (en) Modified coronavirus spike antigen protein and uses thereof
CN116444629B (zh) 一种中东呼吸综合征冠状病毒的重组蛋白及疫苗
US20240218056A1 (en) Nucleocapsid-specific antibodies and methods for the treatment and prevention of sars-cov-2 infection therewith
EP4541806A1 (en) Modified coronavirus spike antigen protein and uses thereof
WO2024125810A1 (en) Formulations for nasal covid-19 vaccines
Abera Bioscience A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV- protects against disease and elicits neutralizing antibodies to wild-type and Delta variants
HK40128066A (zh) Sars-cov-2免疫原性组合物和方法
CN120166938A (zh) SARS-CoV-2免疫原性组合物和方法